The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Cell. 2010 Dec 10;143(6):897-910. doi: 10.1016/j.cell.2010.11.032.
The inositol pyrophosphate IP7 (5-diphosphoinositolpentakisphosphate), formed by a family of three inositol hexakisphosphate kinases (IP6Ks), modulates diverse cellular activities. We now report that IP7 is a physiologic inhibitor of Akt, a serine/threonine kinase that regulates glucose homeostasis and protein translation, respectively, via the GSK3β and mTOR pathways. Thus, Akt and mTOR signaling are dramatically augmented and GSK3β signaling reduced in skeletal muscle, white adipose tissue, and liver of mice with targeted deletion of IP6K1. IP7 affects this pathway by potently inhibiting the PDK1 phosphorylation of Akt, preventing its activation and thereby affecting insulin signaling. IP6K1 knockout mice manifest insulin sensitivity and are resistant to obesity elicited by high-fat diet or aging. Inhibition of IP6K1 may afford a therapeutic approach to obesity and diabetes.
肌醇六磷酸激酶(IP6Ks)家族形成的焦磷酸肌醇 IP7(五磷酸肌醇五磷酸),调节多种细胞活动。我们现在报告,IP7 是 Akt 的一种生理抑制剂,Akt 是一种丝氨酸/苏氨酸激酶,分别通过 GSK3β 和 mTOR 途径调节葡萄糖稳态和蛋白质翻译。因此,在肌醇六磷酸激酶 1(IP6K1)靶向缺失的小鼠的骨骼肌、白色脂肪组织和肝脏中,Akt 和 mTOR 信号显著增强,GSK3β 信号降低。IP7 通过强烈抑制 Akt 的 PDK1 磷酸化来影响该途径,阻止其激活,从而影响胰岛素信号。IP6K1 敲除小鼠表现出胰岛素敏感性,并且对高脂肪饮食或衰老引起的肥胖具有抗性。抑制 IP6K1 可能为肥胖和糖尿病提供一种治疗方法。